Mechanism of Action
GnRH Neuron Inhibition
RFRP-3 acts directly on GnRH neurons via NPFFR1 receptors, hyperpolarizing these neurons and reducing their firing rate. It also acts on gonadotroph cells in the pituitary, directly reducing LH pulse amplitude. The Gi/Go coupling of NPFFR1 decreases cAMP and activates GIRK channels, providing inhibitory tone to GnRH pulse generation.
Environmental Signal Integration
RFRP-3 neurons in the dorsomedial hypothalamic nucleus receive inputs from the suprachiasmatic nucleus (photoperiod), arcuate nucleus (metabolic signals), and stress circuits (CRH neurons). This positioning allows RFRP-3 to integrate seasonal, nutritional, and stress signals to modulate reproductive timing, explaining why stress and malnutrition suppress fertility.
Research Summary
Seasonal Reproduction
PreclinicalIn photoperiod-sensitive species (sheep, hamsters), RFRP-3 neurons are strongly activated during non-breeding seasons (short days), suppressing the HPG axis. Immunoneutralization of RFRP-3 in seasonally anestrous ewes partially restores LH pulsatility. RFRP-3 appears to be the primary seasonal brake on reproductive function.
Stress-Induced Infertility
PreclinicalStress activates RFRP-3 neurons through CRH-dependent mechanisms, contributing to stress-induced suppression of LH secretion. NPFFR1 antagonists partially block stress-induced LH suppression, confirming the role of RFRP-3 in the stress-reproduction interaction. This makes RFRP-3 a potential therapeutic target for stress-related infertility.
Calculate your RFRP-3 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| LH suppression | 1-100 nmol ICV | Single | Intracerebroventricular |
| Stress model | 10-50 nmol SC | Single | Subcutaneous |
Preclinical research only. NPFFR1 antagonists are the therapeutic development direction.
Interactions
Safety Profile
RFRP-3 is an endogenous hypothalamic peptide. Central administration is used in research; no systemic therapeutic use in humans. NPFFR1 antagonists for clinical reproductive applications are in early development. No human clinical data for RFRP-3 itself.
References
- [1]Tsutsui K et al. (2000). A novel avian hypothalamic peptide inhibiting gonadotropin release. Biochemical and Biophysical Research Communications, 275(2), 661-667.
- [2]Kriegsfeld LJ et al. (2006). Identification and characterization of a gonadotropin-inhibitory system in the brains of mammals. PNAS, 103(7), 2410-2415.